India · Delayed Price · Currency is INR Piramal Pharma Statistics
Total Valuation
Piramal Pharma has a market cap or net worth of INR 235.12 billion. The enterprise value is 278.69 billion.
| Market Cap | 235.12B |
| Enterprise Value | 278.69B |
Important Dates
The next estimated earnings date is Tuesday, July 28, 2026.
| Earnings Date | Jul 28, 2026 |
| Ex-Dividend Date | Jul 16, 2025 |
Share Statistics
Piramal Pharma has 1.33 billion shares outstanding. The number of shares has decreased by -0.40% in one year.
| Current Share Class | 1.33B |
| Shares Outstanding | 1.33B |
| Shares Change (YoY) | -0.40% |
| Shares Change (QoQ) | -4.71% |
| Owned by Insiders (%) | 0.19% |
| Owned by Institutions (%) | 24.46% |
| Float | 610.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 129.03 |
| PS Ratio | 2.65 |
| PB Ratio | 2.88 |
| P/TBV Ratio | 5.85 |
| P/FCF Ratio | 30.83 |
| P/OCF Ratio | 14.23 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 29.67, with an EV/FCF ratio of 36.55.
| EV / Earnings | n/a |
| EV / Sales | 3.14 |
| EV / EBITDA | 29.67 |
| EV / EBIT | 182.28 |
| EV / FCF | 36.55 |
Financial Position
The company has a current ratio of 1.51, with a Debt / Equity ratio of 0.70.
| Current Ratio | 1.51 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | 6.47 |
| Debt / FCF | 7.49 |
| Interest Coverage | 0.28 |
Financial Efficiency
Return on equity (ROE) is -4.00% and return on invested capital (ROIC) is 0.78%.
| Return on Equity (ROE) | -4.00% |
| Return on Assets (ROA) | 0.36% |
| Return on Invested Capital (ROIC) | 0.78% |
| Return on Capital Employed (ROCE) | 0.72% |
| Weighted Average Cost of Capital (WACC) | 6.08% |
| Revenue Per Employee | 12.46M |
| Profits Per Employee | -457,781 |
| Employee Count | 7,120 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.33 |
Taxes
In the past 12 months, Piramal Pharma has paid 1.50 billion in taxes.
| Income Tax | 1.50B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.29% in the last 52 weeks. The beta is 0.39, so Piramal Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -12.29% |
| 50-Day Moving Average | 170.07 |
| 200-Day Moving Average | 171.45 |
| Relative Strength Index (RSI) | 58.85 |
| Average Volume (20 Days) | 11,916,196 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Piramal Pharma had revenue of INR 88.69 billion and -3.26 billion in losses. Loss per share was -2.46.
| Revenue | 88.69B |
| Gross Profit | 52.91B |
| Operating Income | 956.90M |
| Pretax Income | -1.76B |
| Net Income | -3.26B |
| EBITDA | 8.35B |
| EBIT | 956.90M |
| Loss Per Share | -2.46 |
Balance Sheet
The company has 13.55 billion in cash and 57.12 billion in debt, with a net cash position of -43.57 billion or -32.83 per share.
| Cash & Cash Equivalents | 13.55B |
| Total Debt | 57.12B |
| Net Cash | -43.57B |
| Net Cash Per Share | -32.83 |
| Equity (Book Value) | 81.63B |
| Book Value Per Share | 61.50 |
| Working Capital | 24.33B |
Cash Flow
In the last 12 months, operating cash flow was 16.53 billion and capital expenditures -8.90 billion, giving a free cash flow of 7.63 billion.
| Operating Cash Flow | 16.53B |
| Capital Expenditures | -8.90B |
| Depreciation & Amortization | 7.40B |
| Net Borrowing | 2.83B |
| Free Cash Flow | 7.63B |
| FCF Per Share | 5.75 |
Margins
Gross margin is 59.66%, with operating and profit margins of 1.08% and -3.68%.
| Gross Margin | 59.66% |
| Operating Margin | 1.08% |
| Pretax Margin | -1.99% |
| Profit Margin | -3.68% |
| EBITDA Margin | 9.42% |
| EBIT Margin | 1.08% |
| FCF Margin | 8.60% |
Dividends & Yields
This stock pays an annual dividend of 0.14, which amounts to a dividend yield of 0.08%.
| Dividend Per Share | 0.14 |
| Dividend Yield | 0.08% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | 0.40% |
| Shareholder Yield | 0.48% |
| Earnings Yield | -1.39% |
| FCF Yield | 3.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Piramal Pharma is 203.00, which is 14.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 203.00 |
| Price Target Difference | 14.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 12.85% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Piramal Pharma has an Altman Z-Score of 2.26 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.26 |
| Piotroski F-Score | 3 |